Clinical trial
MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)
NCT00420420 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00420420 |
|---|---|
| Title | MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011) |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Efficacy of MK0249 for the Symptomatic Treatment of Alzheimer's Disease |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | MK0249, Comparator: Placebo (unspecified) |
| Enrollment | 144 |
| Start date | Nov 1, 2006 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Jan 11, 2007 |
| Last update posted | Feb 12, 2015 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: